Novartis aims to acquire all of Speedel
The Basel pharmaceutical group Novartis plans to fully acquire a research partner – the biotech company Speedel - for about SFr907 million ($882 million).
Novartis announced on Thursday that in a first step it had raised its stake in Speedel, which has a number of projects targeting heart disease, by 51.7 per cent to 61.4 per cent.
In a statement, Novartis said it had bought the shares from major Speedel shareholders – including 21.5 per cent from Speedel chief executive Alice Huxley – for SFr130 per share in cash.
It said it would offer the same price to shareholders for the remaining stake.
The two companies have worked together to develop a hypertension treatment that became the first new medicine for high blood pressure in more than a decade.
Novartis says the Speedel pipeline provides access to many research and development projects targeting heart disease.
More
Switzerland triggers unprecedented special status for Ukrainian refugees
More
Art Basel expands to Qatar despite the drums of war in the Middle East
More
Inside Roche: Taking on the tech sector
More
How Swiss minimalist houses launched a new building style
More
The long road to the Geneva Conventions of 1949
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.